ClinicalTrials.Veeva

Menu
R

Reveal Research Institute | Dallas, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Deucravacitinib
Cemiplimab
TAK-279
Zasocitinib
RO7790121
Ruxolitinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 4 total trials

A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque...

Enrolling
Plaque Psoriasis
Drug: Zasocitinib
Drug: Placebo to match zasocitinib

The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic...

Enrolling
Atopic Dermatitis
Drug: Afimkibart
Drug: Placebo
Locations recently updated

The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.

Enrolling
NonSegmental Vitiligo
Drug: Ruxolitinib Cream
Drug: Vehicle Cream
Locations recently updated

This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin...

Enrolling
Cutaneous Squamous Cell Carcinoma (CSCC)
Procedure: Standard of care
Drug: Cemiplimab

Trial sponsors

Incyte logo
Regeneron Pharmaceuticals logo
Roche logo
Takeda logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems